Suppr超能文献

左甲状腺素单药治疗不能保证所有甲状腺功能减退患者的甲状腺功能正常。

Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients.

机构信息

Endocrine Unit, Department of Clinical and Molecular Biomedicine, University of Catania Medical School, Garibaldi-Nesima Hospital, Catania, Italy.

出版信息

PLoS One. 2011;6(8):e22552. doi: 10.1371/journal.pone.0022552. Epub 2011 Aug 1.

Abstract

CONTEXT

Levothyroxine monotherapy is the treatment of choice for hypothyroid patients because peripheral T4 to T3 conversion is believed to account for the overall tissue requirement for thyroid hormones. However, there are indirect evidences that this may not be the case in all patients.

OBJECTIVE

To evaluate in a large series of athyreotic patients whether levothyroxine monotherapy can normalize serum thyroid hormones and thyroid-pituitary feedback.

DESIGN

Retrospective study.

SETTING

Academic hospital.

PATIENTS

1,811 athyreotic patients with normal TSH levels under levothyroxine monotherapy and 3,875 euthyroid controls.

MEASUREMENTS

TSH, FT4 and FT3 concentrations by immunoassays.

RESULTS

FT4 levels were significantly higher and FT3 levels were significantly lower (p<0.001 in both cases) in levothyroxine-treated athyreotic patients than in matched euthyroid controls. Among the levothyroxine-treated patients 15.2% had lower serum FT3 and 7.2% had higher serum FT4 compared to euthyroid controls. A wide range of FT3/FT4 ratios indicated a major heterogeneity in the peripheral T3 production capacity in different individuals. The correlation between thyroid hormones and serum TSH levels indicated an abnormal feedback mechanism in levothyroxine-treated patients.

CONCLUSIONS

Athyreotic patients have a highly heterogeneous T3 production capacity from orally administered levothyroxine. More than 20% of these patients, despite normal TSH levels, do not maintain FT3 or FT4 values in the reference range, reflecting the inadequacy of peripheral deiodination to compensate for the absent T3 secretion. The long-term effects of chronic tissue exposure to abnormal T3/T4 ratio are unknown but a sensitive marker of target organ response to thyroid hormones (serum TSH) suggests that this condition causes an abnormal pituitary response. A more physiological treatment than levothyroxine monotherapy may be required in some hypothyroid patients.

摘要

背景

左旋甲状腺素单药治疗是甲状腺功能减退患者的首选治疗方法,因为外周 T4 向 T3 的转化被认为可以满足甲状腺激素的整体组织需求。然而,有间接证据表明,并非所有患者都是如此。

目的

在大量甲状腺功能减退患者中评估左旋甲状腺素单药治疗是否可以使血清甲状腺激素和甲状腺-垂体反馈正常化。

设计

回顾性研究。

地点

学术医院。

患者

1811 例甲状腺功能减退患者在左旋甲状腺素单药治疗下 TSH 水平正常,3875 例甲状腺功能正常对照者。

测量

用免疫分析法测量 TSH、FT4 和 FT3 浓度。

结果

与匹配的甲状腺功能正常对照组相比,接受左旋甲状腺素治疗的甲状腺功能减退患者的 FT4 水平显著升高,FT3 水平显著降低(两种情况下均 p<0.001)。在接受左旋甲状腺素治疗的患者中,15.2%的患者血清 FT3 较低,7.2%的患者血清 FT4 较高。FT3/FT4 比值范围广泛表明不同个体外周 T3 产生能力存在较大异质性。甲状腺激素与血清 TSH 水平之间的相关性表明,接受左旋甲状腺素治疗的患者存在异常的反馈机制。

结论

接受口服左旋甲状腺素治疗的甲状腺功能减退患者 T3 产生能力具有高度异质性。尽管 TSH 水平正常,但这些患者中有 20%以上的患者未能维持 FT3 或 FT4 值在参考范围内,这反映了外周脱碘作用不足以补偿缺失的 T3 分泌。长期慢性组织暴露于异常 T3/T4 比值的影响尚不清楚,但对甲状腺激素(血清 TSH)反应敏感的标志物提示这种情况会导致垂体反应异常。一些甲状腺功能减退患者可能需要比左旋甲状腺素单药治疗更具生理意义的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7180/3148220/4930993f40a4/pone.0022552.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验